Literature DB >> 16822818

Insulin sensitivity in patients with primary aldosteronism: a follow-up study.

Cristiana Catena1, Roberta Lapenna, Sara Baroselli, Elisa Nadalini, Gianluca Colussi, Marileda Novello, Grazia Favret, Alessandra Melis, Alessandro Cavarape, Leonardo A Sechi.   

Abstract

CONTEXT: The relationship between aldosterone and glucose metabolism is poorly understood, and there is substantial disparity among findings of studies that have examined glucose tolerance and insulin sensitivity in patients with primary aldosteronism.
OBJECTIVE: The objective of the study was to determine the outcome of glucose tolerance and insulin sensitivity in patients with primary aldosteronism after treatment.
DESIGN: This was a prospective study of patients who received a diagnosis of primary aldosteronism and were followed up for an average period of 5.7 yr (range, 3-9 yr).
SETTING: The study was conducted at a university referral center. PATIENTS: A consecutive sample of 47 patients with tumoral or idiopathic aldosteronism was followed up after either surgical or medical treatment. Patients with primary aldosteronism were compared with 247 patients with essential hypertension with the same severity and duration of disease and 102 normotensive subjects. MAIN OUTCOME MEASURES: Short- and long-term changes in glucose tolerance and insulin sensitivity were measured.
RESULTS: After adjustment for age, gender, and body mass index, patients with primary aldosteronism had greater homeostasis model assessment index (P < 0.05) and plasma insulin response to an oral glucose load (P < 0.05) and lower quantitative insulin sensitivity check index (P < 0.01) than normotensive controls. Changes in insulin sensitivity were significantly greater in essential hypertension than primary aldosteronism, and this difference was confirmed by assessment with the hyperinsulinemic-euglycemic clamp (P < 0.01). Treatment of primary aldosteronism decreased blood pressure significantly, and during the initial 6 months of follow-up, parameters of insulin sensitivity were restored to normal. Analysis of subsequent follow-up showed nonsignificant changes in glucose metabolism parameters in both adrenalectomized and spironolactone-treated patients.
CONCLUSIONS: Insulin resistance is present in patients with tumoral and idiopathic aldosteronism, but the defect appears less severe than in patients with essential hypertension. Treatment with surgery or aldosterone antagonists restores rapidly and persistently normal sensitivity to insulin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822818     DOI: 10.1210/jc.2006-0736

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  80 in total

Review 1.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.

Authors:  J M Luther; P Luo; M T Kreger; M Brissova; C Dai; T T Whitfield; H S Kim; D H Wasserman; A C Powers; N J Brown
Journal:  Diabetologia       Date:  2011-04-26       Impact factor: 10.122

Review 3.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 4.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

5.  Aldosterone aggravates glucose intolerance induced by high fructose.

Authors:  Shamshad J Sherajee; Kazi Rafiq; Daisuke Nakano; Hirohito Mori; Hideki Kobara; Hirofumi Hitomi; Yoshihide Fujisawa; Hiroyuki Kobori; Tsutomu Masaki; Akira Nishiyama
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

Review 6.  Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Authors:  Badhma Valaiyapathi; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 7.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

8.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 9.  THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.

Authors:  Anna Grodzinsky; Suzanne V Arnold; Dany Jacob; Boris Draznin; Mikhail Kosiborod
Journal:  Endocr Pract       Date:  2016-12-14       Impact factor: 3.443

Review 10.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.